Transient YAP/TAZ inhibition exposes therapeutic vulnerabilities in advanced cancers
Jessen, M.; Kim, K.; Tollot-Wegner, M.; Vranesic, A. C.; Doenmez, C.; Junker, C.; Lehmann, T.; Khandelwal, A.; Kurlishchuk, Y.; Huenniger, T.; Ritter, C.; Di Napoli, E.; Krishnan, M. S.; Buck, V.; Muth, S.; Tang, T.; Rosenwald, A.; Inverso, D.; Radsak, M.; Paciello, O.; von Eyss, B.
Show abstract
YAP and TAZ, key effectors of the Hippo pathway, are frequently hyperactivated in cancer, where they drive tumor progression and resistance to therapy. Their oncogenic activity relies on interaction with TEAD transcription factors, making the TEAD-YAP/TAZ complex an attractive therapeutic target. Using translational mouse models, we demonstrate that sustained systemic YAP/TAZ depletion leads to severe side effects. However, even transient YAP/TAZ inhibition alone is sufficient to suppress tumor growth in advanced stages. Mechanistically, YAP/TAZ activity promotes T cell exclusion from the tumors by inducing target genes involved in tissue remodeling. Consequentially, YAP/TAZ inhibition induces immune infiltration, but the infiltrating T cells rapidly become exhausted. Combining YAP/TAZ inhibition with immune checkpoint blockade (ICB) overcomes this exhaustion and sensitizes previously resistant tumors to immunotherapy.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors 96%
- Agonistic CD40 antibody therapy induces tertiary lymphoid structures but impairs the response to immune checkpoint blockade in glioma 96%
- Epithelial-mesenchymal plasticity determines estrogen receptor positive (ER+) breast cancer dormancy and reacquisition of an epithelial state drives awakening 96%
Similar papers in this journal
Similar papers in this journal
- Aberrant cell state plasticity mediated by developmental reprogramming precedescolorectal cancer initiation 95%
- An in vivo screen identifies NAT10 as a master regulator of brain metastasis 95%
- TET2 regulates early and late transitions in exhausted CD8+ T-cell differentiation and limits CAR T-cell function 94%
Similar papers in this journal
Similar papers in this journal
- CRISPR/Cas9 screen identifies KRAS-induced COX-2 as a driver of immunotherapy resistance in lung cancer 96%
- Combinatorial tumor suppressor inactivation efficiently initiates lung adenocarcinoma with therapeutic vulnerabilities 95%
- Neuroblastoma formation requires unconventional CD4 T cells and myeloid amino acid metabolism 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.